secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2023-02-10T23:59:59+00:00
Accession:  0001683168-23-000716
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma signs research agreement with Jewish General Hospital for Adva-27a anticancer compound
--------------------------------------------------------------------------------

- 3-year agreement to advance Adva-27a through IND-enabling studies; JGH paid fair market value for services.
- Sunshine retains exclusive ownership of all improvements and research results; JGH receives 3% royalty for 20 years on net revenues from IP.
- Research led by Dr. Gerald Batist, Head of Oncology at JGH and Director of the McGill Centre for Translational Research in Cancer.
- If results are conclusive, parties will negotiate terms to conduct a Phase I clinical trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823000716/0001683168-23-000716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823000716/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-000716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer